JP2019513706A - オナプリストン代謝物質組成物及び方法 - Google Patents

オナプリストン代謝物質組成物及び方法 Download PDF

Info

Publication number
JP2019513706A
JP2019513706A JP2018549568A JP2018549568A JP2019513706A JP 2019513706 A JP2019513706 A JP 2019513706A JP 2018549568 A JP2018549568 A JP 2018549568A JP 2018549568 A JP2018549568 A JP 2018549568A JP 2019513706 A JP2019513706 A JP 2019513706A
Authority
JP
Japan
Prior art keywords
cells
onapristone
methyl
patient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018549568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513706A5 (OSRAM
Inventor
ステファン・プロニウク
スーザン・ヤニ
Original Assignee
コンテキスト・バイオファーマ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コンテキスト・バイオファーマ・インコーポレイテッド filed Critical コンテキスト・バイオファーマ・インコーポレイテッド
Publication of JP2019513706A publication Critical patent/JP2019513706A/ja
Publication of JP2019513706A5 publication Critical patent/JP2019513706A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018549568A 2016-03-21 2017-03-20 オナプリストン代謝物質組成物及び方法 Pending JP2019513706A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662310944P 2016-03-21 2016-03-21
US62/310,944 2016-03-21
PCT/US2017/023256 WO2017165315A1 (en) 2016-03-21 2017-03-20 Onapristone metabolite compositions and methods

Publications (2)

Publication Number Publication Date
JP2019513706A true JP2019513706A (ja) 2019-05-30
JP2019513706A5 JP2019513706A5 (OSRAM) 2020-04-30

Family

ID=59848182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018549568A Pending JP2019513706A (ja) 2016-03-21 2017-03-20 オナプリストン代謝物質組成物及び方法

Country Status (3)

Country Link
US (1) US20170266204A1 (OSRAM)
JP (1) JP2019513706A (OSRAM)
WO (1) WO2017165315A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391191B (es) 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
MX2018007154A (es) 2015-12-15 2019-01-10 Context Biopharma Inc Composiciones de onapristona amorfa y metodos para hacer las mismas.
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041695A (ja) * 1983-06-15 1985-03-05 シエ−リング・アクチエンゲゼルシヤフト １３α−アルキルゴナン、その製造方法及び該化合物を含有する、抗ゲスタ−ゲン作用を有する製剤製品
WO2009134725A2 (en) * 2008-04-28 2009-11-05 Repros Therapeutics Inc. Compositions and methods for treating progesterone-dependent conditions
WO2014164861A1 (en) * 2013-03-12 2014-10-09 Arno Therapeutics Onapristone polymorphic forms and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041695A (ja) * 1983-06-15 1985-03-05 シエ−リング・アクチエンゲゼルシヤフト １３α−アルキルゴナン、その製造方法及び該化合物を含有する、抗ゲスタ−ゲン作用を有する製剤製品
WO2009134725A2 (en) * 2008-04-28 2009-11-05 Repros Therapeutics Inc. Compositions and methods for treating progesterone-dependent conditions
WO2014164861A1 (en) * 2013-03-12 2014-10-09 Arno Therapeutics Onapristone polymorphic forms and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEROIDS, vol. Vol.44(4), JPN6021003343, 1984, pages 349 - 372, ISSN: 0004613049 *

Also Published As

Publication number Publication date
US20170266204A1 (en) 2017-09-21
WO2017165315A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
US20230255995A1 (en) Nicotinyl Riboside Compounds and Their Uses
RU2745678C2 (ru) Способы лечения рака
EP2200599B1 (en) 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
JP2019513706A (ja) オナプリストン代謝物質組成物及び方法
JP2018138594A (ja) オナプリストン多形体及び使用方法
KR20180094965A (ko) 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도
EP3595725B1 (en) Combination therapies for the treatment of breast cancer
KR20250159077A (ko) 세포 증식성 질환의 치료 또는 예방을 위한 쿠마린 유도체
CA3224544A1 (en) Treatment of immune-related disorders, kidney disorders, liver disorders, hemolytic disorders, and oxidative stress-associated disorders using nrh, narh and reduced derivatives thereof
EP3007693A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
JP2019513706A5 (OSRAM)
WO2022232597A1 (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
AU2014347357A1 (en) Methods and pharmaceutical formulations for treatment of selective estrogen-receptor modulator-induced adverse drug reactions
WO2021048412A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
CN106061505A (zh) 用于治疗癌症的含pi3k抑制剂的药物组合
AU2019273656B2 (en) Pharmaceutical compounds for use in treating Huntington's disease
CA3032698C (en) Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
AU2006221479A1 (en) Method of treating liver cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200319

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012